HCA Healthcare, Inc. (HCA) · Oct 27, 2026 · Earnings
Beat — GAAP EPS $7.27 vs ~$6.65 consensus; revenue $19.85B vs ~$19.33B
HCA Healthcare earnings beat Q3 expectations and put 2026 guidance in its upper half, but uninsured volume cost roughly $400M before tax.
Situation: HCA is a scaled hospital and ambulatory-care operator working through the loss of enhanced exchange subsidies and broader federal health-policy pressure, which are pushing more patients into uninsured care and weakening reimbursement quality. Its prior outlook had already been reset lower in July, so this quarter was mainly a test of whether volume growth and cost control could absorb that damage.
| Metric | Q3 2026 | Comparison |
|---|---|---|
| Revenue | $19.849B | $19.161B in Q3 2025; published consensus ~$19.33B |
| GAAP diluted EPS | $7.27 | $6.96 in Q3 2025; published consensus ~$6.65 |
| Adjusted EPS | $7.22 | $6.96 in Q3 2025 |
| Adjusted EBITDA | $3.918B | $3.870B in Q3 2025 |
| Adjusted EBITDA margin | 19.7% | 20.2% in Q3 2025 |
| Same-facility equivalent admissions | +3.0% | +2.3% in Q3 2025 |
| Estimated pretax payer-mix impact | Approximately $400M unfavorable | Primarily from higher uninsured exchange volume |
| 2026 revenue guidance | $77.0B–$79.5B | Management now expects the upper half of the existing range |
| 2026 adjusted EBITDA guidance | $15.4B–$16.1B | Management now expects the upper half of the existing range |
The quarter cleared a lowered bar by a meaningful margin. Revenue rose 3.6%, while GAAP EPS of $7.27 and adjusted EPS of $7.22 were well above the roughly $6.65 consensus; revenue also exceeded the roughly $19.33 billion expectation. The result is better than the market’s already-muted setup, not merely a year-over-year improvement. The filing reported, “Revenues in the third quarter of 2026 totaled $19.849billion, compared to $19.161billion in the third quarter of 2025.” (Operating Results Summary; Condensed Consolidated Comprehensive Income Statements)
Underlying demand was stronger than the headline profit growth suggests. Same-facility equivalent admissions accelerated to 3.0%, emergency-room visits rose 5.1%, and occupancy improved, giving HCA more volume to work with. But surgical activity remained weak: same-facility inpatient surgeries fell 1.4% and outpatient surgeries fell 3.7%. The filing states, “Same facility admissions increased 2.7 percent and same facility equivalent admissions increased 3.0 percent in the third quarter of 2026, compared to the prior year period.” 〔0〕 (Operating Statistics)
The payer problem is still the central business constraint, but HCA absorbed it better than expected. The company estimated that the shift toward uninsured patients reduced pretax income by approximately $400 million, yet adjusted EBITDA still grew 1.2%. That resilience came with a cost: adjusted EBITDA margin compressed from 20.2% to 19.7%, and net income declined 3.9%. The filing says, “The Company estimates this payer mix shift had an unfavorable impact on income before income taxes of approximately $400million during the third quarter.” (Third-quarter operating discussion)
Management effectively reaffirmed the reduced annual outlook at its better end. HCA did not raise the July ranges, but now expects full-year operating results in the upper half of them, which is an incremental improvement in confidence after the earlier guidance cut. The filing reported, “The Company now believes its full year operating results will be in the upper half of its 2026 estimated guidance ranges previously issued on July 14, 2026.” 〔1〕 (2026 Guidance)
Cash generation supported continued shareholder returns, though leverage remains part of the backdrop. Operating cash flow was $4.461 billion in the quarter, while HCA repurchased $2.970 billion of stock and ended September with $50.493 billion of debt against $908 million of cash. That capital return is supportive of per-share results, but it also leaves less room for error if uninsured care and reimbursement pressure persist. The filing states, “During the third quarter of 2026, the Company repurchased 7.230 million shares of its common stock at a cost of $2.970billion.” (Balance Sheet and Cash Flows from Operations)
Bottom line: This was a genuine earnings beat against a deliberately lowered bar, with stronger volumes and better execution offsetting a large uninsured-payer hit. The business is not out of the policy-pressure woods, but the filing improves confidence that HCA can still land 2026 toward the upper end of its reset outlook.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!